Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873248 · ClinicalTrials.gov registry record · Early Phase 1
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
A Early Phase 1 study of Neuroendocrine Tumors, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT01873248 is a Early Phase 1 study of Neuroendocrine Tumors that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 100 participants, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01873248, a Early Phase 1 study of Neuroendocrine Tumors, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG 68Ga-DOTATATE
Study Locations (1)
California
- University of California Los Angeles, Nuclear Medicine Clinic of the Department of Molecular and Medical Pharmacology - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2013-08-26 |
| Est. Completion | 2017-06-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01873248
The ClinicalTrials.gov registry entry for NCT01873248 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (44% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-DOTATATE is the first listed.
NCT01873248 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01873248 about?
NCT01873248 is a clinical study titled "Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective". Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.
What is the current status of trial NCT01873248?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2013-08-26. Estimated completion is 2017-06-16.
What conditions does trial NCT01873248 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT01873248?
The interventions under investigation include: 68Ga-DOTATATE (DRUG).
Who is sponsoring clinical trial NCT01873248?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01873248 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
ACTIVE NOT RECRUITING · Early Phase 1
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.